VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 6, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the “Company”) announces that new tests have shown the Company’s T36® formulation to be completely effective against Methicillin-Resistant Staphylococcus aureus (“MRSA”) within one minute. First discovered in 1961 in the UK, MRSA is now found worldwide and is able to survive treatment with a number of antibiotics, including penicillin, methicillin, and cephalosporins. Often referred to in the press as a “superbug”, MRSA is especially troublesome in hospital-acquired infections but is increasingly found outside of medical facilities.
